Prevalence and Overlap of Cardiovascular, Kidney, and Metabolic Diseases in Korea: A Population-based Study

Sponsor
Novo Nordisk A/S
Study ID
NCT07673822
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • No treatment given — OTHER
    No treatment given

Study Details

This study tests the prevalence and characteristics of overlapping obesity, type 2 diabetes (T2D), cardiovascular disease (CVD), chronic kidney disease (CKD), and metabolic dysfunction-associated steatotic liver disease \[MASLD/Metabolic Dysfunction-Associated Steatohepatitis (MASH)\], osteoarthritis, hypertension, and dyslipidemia. The purpose of the study is to measure how common cardiovascular, kidney, and metabolic diseases are in the Korean adult population and how often they occur together (overlap) over time (2013-2023). Participants will not receive any study medicine as this is an observational analysis of existing survey data. The study does not involve a new investigational drug; it analyses health and outcome data collected in routine practice and national surveys.

Key Dates

First listed
Jun 29, 2026
Start date
Jun 8, 2026
Status verified
Jun 2026
Primary completion
Aug 3, 2026
Completion
Aug 3, 2026

Study Design

Enrollment
800,000 participants (estimated)

Arms

  • Arm: MASLD
    Participants with MASLD where the date of first MASLD identification at biennial screening (2013-2018), after the greater than or equal to (≥) 1-year washout window; follow-up continues until death, loss of NHIS eligibility, or end of available data.
  • Arm: Heart Failure (HF)
    Participants for whom the date of first HF diagnosis is at biennial screening (2013-2028), after the ≥1-year washout window; follow-up continues for a minimum of 5 years from the index date.
  • Arm: CKM Stage
    Participants were categorized according to CKM staging (Stages 0-4), based on their CKM stage assessed at the initial national health screening, after the ≥1-year washout window; follow-up continues until death, loss of National Health Insurance Service (NHIS) eligibility, or end of available data.
  • Arm: High Obesity
    Participants with pre-specified obesity participants of interest tier that indicating significant overweight and were classified into three categories: 1) Body Mass Index (BMI) greater than or equal to (≥) 27 kg/m\^2 with established CVD. 2) BMI ≥27 kg/m\^2 with one or more obesity-related comorbidities. 3) BMI ≥25 kg/m\^2 and less than (\<) 30 kg/m\^2 with 1 or more obesity-related comorbidities.
  • Arm: Atherosclerotic Cardiovascular Disease (ASCVD) with or without CKD
    Participants with ASCVD where the first ASCVD identification occurred during biennial screening (2013-2018), after the ≥1-year washout window.

Primary Outcome Measure

Proportion of participants with obesity (BMI ≥25 kilograms per square meter (kg/m^2)) [ Time Frame: 2013-2018 (Annually) ]

Find similar trials

Nationwide
Chronic kidney disease trialsType 2 diabetes trialsObesity / overweight trialsNephrology trialsKidney disease trialsEndocrinology trialsMetabolic health trialsWeight loss trials

Related Studies